// App-Quantinova.ai

e15125 : Radiomic profiles via machine learning to predict response, overall survival, and KRAS status in metastatic colorectal tumors treated with FOLFOX/bevacizumab/hydroxychloroquine.

Researchers

Presenter

  • Saima Rathore

Principal Investigators

  • Mark H. O'Hara

  • Thomas Benjamin Karasic

  • Maryann Redlinger

  • Mark Alan Rosen

  • Christos Davatzikos

  • Peter O'Dwyer

Medical Centers

  • Center for Biomedical Image Computing and Analytics, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • University of Pennsylvania, Philadelphia, PA

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • KRAS proto-oncogene, GTPase

  • Sustained virological response

Drug/Treatment

  • Hydroxychloroquine

  • Bevacizumab

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved